AXSM Axsome Therapeutics Inc.

9.01
+0.53  (+6%)
Previous Close 8.48
Open 8.47
Price To Book 450.5
Market Cap 294575048
Shares 32,694,234
Volume 954,041
Short Ratio
Av. Daily Volume 2,514,921

SEC filingsSee all SEC filings

  1. 8-K - Current report 19569842
  2. 8-K - Current report 19550359
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19545519
  4. 8-K - Current report 19514569
  5. 8-K - Current report 19512167

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 1Q 2019.
AXS-05
Smoking cessation
Phase 2/3 interim analysis December 10, 2018 noted DSMB recommendation to continue trial. Interim effiacy analysis due 2019 with top-line data due 2H 2019 – 1H 2020.
AXS-05 ADVANCE-1
Agitation in patients with Alzheimer’s disease (AD)
Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 final data due 1Q 2019.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 interim efficacy analysis January 9, 2017 recommended trial continue to full enrollment.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 trial planned for 1Q 2019. SPA received February 6, 2019.
AXS-07 - MOMENTUM
Migraine
Phase 2 data met primary endpoint - January 7, 2019.
AXS-05 ASCEND
Major Depressive Disorder
Phase 2 trial initiation announced January 30, 2019 with top-line data due 2Q 2019.
AXS-12
Narcolepsy

Latest News

  1. Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine
  2. Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
  3. 3 Small-Cap Stocks With Big-Cap Potential
  4. Is This Why Axsome Therapeutics Is Losing Ground Again Today?
  5. Market Rally Extends to Biotech
  6. This Stock Generated 25X Returns In Just Five Years: Could BTCY Be At The Same Crossroads?
  7. Axsome Therapeutics Has Surged Over 200% in the Last Two Days
  8. Here's Why Axsome Therapeutics Has Been a Rocket Ship This Week
  9. Axsome Therapeutics: Do Not Buy AXSM Stock After Its Monster Rally
  10. Portfolios Making Up For Lost Time
  11. The Next Big Biotech Breakout
  12. The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase
  13. Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility
  14. AXSM News: Why Axsome Therapeutics Stock Is Skyrocketing Today
  15. 4 Healthcare Stocks Making Moves On Monday (1/7/19)
  16. Axsome's stock nearly triples on heavy volume after positive trial of depression treatment
  17. Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder
  18. These 4 Healthcare Stocks May Test December Highs
  19. New Research: Key Drivers of Growth for Trimble, Maxar Technologies, MagnaChip Semiconductor, Palo Alto Networks, AAR, and Axsome Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

SEC Filings

  1. 8-K - Current report 19569842
  2. 8-K - Current report 19550359
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19545519
  4. 8-K - Current report 19514569
  5. 8-K - Current report 19512167
  6. 8-K - Current report 19512084
  7. 8-K - Current report 181253711
  8. 8-K - Current report 181224852
  9. 8-K - Current report 181202452
  10. 8-K - Current report 181180394